Inhibitors of immune-checkpoint proteins, such as PD1, PD-L1, VISTA, Tim3 and Lag3, have indicated broad and diverse opportunities to increase antitumor immunity by enhancing T cell activity with the potential to produce durable clinical responses. To meet these needs, we have developed stable cell line products expressing the most popular immune checkpoints to accelerate your immunotherapy drug discovery and achieve US Food and Drug Administration (FDA) approval. All these stable cells are developed for screening high affinity antibodies against immune checkpoint proteins.
- High protein expression at the cell surface validated by FACS
- Stable cell lines for increased reliability and reproducibility (over 15 passages)
- Ready to use hot targets, saving 3-5 months of drug discovery program